These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 8310199)

  • 21. [Diagnosis of and therapy for patients with diabetic nephropathy].
    Doi T
    Nihon Naika Gakkai Zasshi; 2004 Mar; 93(3):569-73. PubMed ID: 15052822
    [No Abstract]   [Full Text] [Related]  

  • 22. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease.
    Ahmed AK; Kamath NS; El Kossi M; El Nahas AM
    Nephrol Dial Transplant; 2010 Dec; 25(12):3977-82. PubMed ID: 19820248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Progression of chronic renal insufficiency and its prevention using angiotensin converting enzyme inhibitors and angiotensin antagonists].
    Tesar V
    Vnitr Lek; 2003 May; 49(5):365-9. PubMed ID: 12908169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
    Lancet; 1997 Jun; 349(9069):1857-63. PubMed ID: 9217756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment and physiopathology of diabetic nephropathies].
    Nakamoto Y; Inomata S
    Nihon Naika Gakkai Zasshi; 1990 Feb; 79(2):200-4. PubMed ID: 2193992
    [No Abstract]   [Full Text] [Related]  

  • 26. Diabetic nephropathy.
    Rabkin R
    Clin Cornerstone; 2003; 5(2):1-11. PubMed ID: 12800476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).
    Ruggenenti P; Perna A; Mosconi L; Matalone M; Pisoni R; Gaspari F; Remuzzi G
    Kidney Int Suppl; 1997 Dec; 63():S54-7. PubMed ID: 9407422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pathogenicity of glomerular hyperfiltration, a question of glomerular tolerance?].
    Wüstenberg PW; Dabels J
    Z Gesamte Inn Med; 1990 Apr; 45(8):210-4. PubMed ID: 2198716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complete remission of diabetic nephropathy in a type 1 diabetic patient with near-nephrotic range proteinuria and reduced renal function.
    Haraguchi K; Hara S; Ubara Y; Tanaka S; Nukui I; Shimura H; Ohashi K; Kobayashi T
    Diabetes Res Clin Pract; 2009 Mar; 83(3):295-9. PubMed ID: 19162360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of ACE inhibitors on renal function in incipient and overt diabetic nephropathy.
    Parving HH
    J Diabetes Complications; 1996; 10(3):133-5. PubMed ID: 8807457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of angiotensin-converting enzyme inhibitors in chronic progressive renal disease.
    Brouhard BH; Irwin KC; Cunningham RJ; Stowe NT
    Cleve Clin J Med; 1991; 58(2):184-90. PubMed ID: 2025923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anaemia is common and predicts mortality in diabetic nephropathy.
    Joss N; Patel R; Paterson K; Simpson K; Perry C; Stirling C
    QJM; 2007 Oct; 100(10):641-7. PubMed ID: 17921197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surrogate endpoints and renal protection: focus on microalbuminuria.
    Epstein M; Parving HH; Ruilope LM
    Blood Press Suppl; 1997; 2():52-7. PubMed ID: 9495628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Progression of chronic renal insufficiency].
    Rossert J; Fischer E; Venetz JP
    Nephrologie; 1999; 20(1):3-7. PubMed ID: 10081030
    [No Abstract]   [Full Text] [Related]  

  • 35. [What are the facts in the treatment of diabetic nephropathy?].
    Kohler SM; Krämer BK
    Dtsch Med Wochenschr; 1993 Mar; 118(12):433-7. PubMed ID: 8467738
    [No Abstract]   [Full Text] [Related]  

  • 36. [Treatment of diabetic nephropathies].
    Arakawa M; Suzuki Y
    Nihon Naika Gakkai Zasshi; 1994 Sep; 83(9):1642-7. PubMed ID: 7798763
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of ACE-inhibitors in hypertensive and normotensive diabetic patients with diabetic nephropathie.
    Henrichs HR
    Horm Metab Res Suppl; 1990; 22():57-65. PubMed ID: 2202629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Approach to the treatment of diabetic nephropathy.
    Burke JM
    Pharm Pract Manag Q; 1997 Jul; 17(2):26-35. PubMed ID: 10168175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diabetic nephropathy: where are we on the journey from pathophysiology to treatment?
    Gallagher H; Suckling RJ
    Diabetes Obes Metab; 2016 Jul; 18(7):641-7. PubMed ID: 26743887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical impact of albuminuria in diabetic nephropathy.
    Wada T; Shimizu M; Toyama T; Hara A; Kaneko S; Furuichi K
    Clin Exp Nephrol; 2012 Feb; 16(1):96-101. PubMed ID: 21830044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.